MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR AND PLACEBO-CONTROLLED TRIAL OF A CORTICOTROPIN-RELEASING FACTOR RECEPTOR-1 ANTAGONIST IN GENERALIZED ANXIETY DISORDER
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR AND PLACEBO-CONTROLLED TRIAL OF A CORTICOTROPIN-RELEASING FACTOR RECEPTOR-1 ANTAGONIST IN GENERALIZED ANXIETY DISORDER
复制标题
DOI：
10.1002/da.20695
复制
发表时间：
2010-05-01
影响因子：
7.4
通讯作者：
Stock, Elyse G.
中科院分区：
文献类型：
--
作者：
Coric, Vladimir;Feldman, Howard H.;Stock, Elyse G.
背景资料：促肾上腺皮质激素释放因子（CRF）受体的拮抗作用已被假设为开发新型抗焦虑药的潜在靶点。本研究旨在确定选择性CRF-1受体拮抗剂paccessfont治疗广泛性焦虑症（GAD）的安全性和有效性。方法：这是一项多中心、随机、双盲、安慰剂对照和活性对照试验。260例患者以2：2：1的比例随机分配至paccessfont 100 mg/天（1周负荷剂量300 mg/天后）、安慰剂或艾司西酞普兰20 mg/天组。首要结果是汉密尔顿焦虑量表总分从基线到终点（第8周）的平均变化。结果：100 mg/d的Pacescefont未分离。安慰剂对首因性结局指标的影响。在第1、2、3、6和8周，半效力的活性对照组艾司西酞普兰20 mg/天显示出与安慰剂显著分离的疗效（P
Background: Antagonism of corticotropin-releasing factor (CRF) receptors has been hypothesized as a potential target for the development of novel anxiolytics. This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD). Method: This was a multicenter; randomized, double-blind, placebo-controlled and active comparator trial. Two hundred and sixty patients were randomly assigned to pexacerfont 100 mg/day (after a 1 week loading dose of 300 mg/day), placebo or escitalopram 20 mg/day in a 2:2:1 ratio. The primacy outcome was the mean change from baseline to end point (week 8) in the Hamilton Anxiety Scale total score. Results: Pexacerfont 100 mg/day did not separate from. placebo on the primacy outcome measure. The half-powered active comparator arm, escitalopram 20 mg/day, demonstrated efficacy with significant separation from placebo at weeks 1, 2, 3, 6, and 8 (P